Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jan Van De Winkel
AddedMar 31, 2024
UpdatedMay 31, 2026
Jan Van De Winkel

Jan Van De Winkel

Co-Founder & CEO, Genmab

CrunchbaseLinkedIn

Jan Van De Winkel's Career

Genmab
Genmab

Copenhagen, Capital Region of Denmark, DK

Co-Founder & CEO· C-Suite · Management
Thuja Capital
Thuja Capital

Utrecht, Utrecht, NL

Board Member· Board
Hookipa Pharma
Hookipa Pharma

New York City, NY, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jan Van De Winkel's Career

Genmab
Genmab
Public$204.3M2k1999Copenhagen, Capital Region of Denmark, DK
Co-Founder & CEO· C-Suite · Management

Leadership at Genmab

Deirdre ConnellyDeirdre ConnellyBoard Member
Elizabeth O’FarrellElizabeth O’FarrellBoard Member
Paolo PaolettiPaolo PaolettiBoard Member
Mijke ZachariasseMijke ZachariasseBoard Member
Don DrakemanDon DrakemanCo-Founder
Pernille ErenbjergPernille ErenbjergBoard Member

Similar to Genmab

GenentechGenentechSouth San Francisco, CA, USBiopharmaceuticalsest. 1976GenentechSouth San Francisco, CA, US · est. 1976

Genentech, Inc.: A pioneering US biotech firm, operating as an independent subsidiary of Roche.

Public13.5k
MacroGenicsMacroGenicsRockville, MD, USest. 2000MacroGenicsRockville, MD, US · est. 2000

US-based MacroGenics, Inc. develops novel biologics for cancer, autoimmune disorders, and infectious diseases.

Public · $165.9M357
SeagenSeagenBothell, WA, USCancer Treatmentsest. 1997SeagenBothell, WA, US · est. 1997

Global biotech innovator developing cancer treatments.

Public · $1.7B3.3k
AdimabAdimabLebanon, NH, USTherapeutic Antibodiesest. 2007AdimabLebanon, NH, US · est. 2007

Adimab, LLC: A global biotech firm specializing in yeast-based therapeutic human antibodies.

Public · $45.5M149
Thuja Capital
Thuja Capital
Investment FirmInvestment Firm302006Utrecht, Utrecht, NL
Board Member· Board

Leadership at Thuja Capital

Peter van BrummelenPeter van BrummelenBoard Member
Markwin VeldersMarkwin VeldersBoard Member
Staf Van ReetStaf Van ReetBoard Member
Werner CautreelsWerner CautreelsBoard Member
Harrold Van BarlingenHarrold Van BarlingenBoard Member

Similar to Thuja Capital

Erasmus MC Biomedical FundErasmus MC Biomedical FundNaarden, North Holland, NLest. 2007Erasmus MC Biomedical FundNaarden, North Holland, NL · est. 2007

Investing in Dutch biomedical ventures.

Investment Firm5
Tiin CapitalTiin CapitalNaarden, North Holland, NLest. 1998Tiin CapitalNaarden, North Holland, NL · est. 1998

TIIN Capital: A venture capital firm investing in innovative early and later-stage Dutch companies.

Investment Firm20
Assiduity CapitalAssiduity CapitalAmsterdam, North Holland, NLest. 2019Assiduity CapitalAmsterdam, North Holland, NL · est. 2019

Amsterdam-based Assiduity Capital is a venture capital firm specializing in healthcare investments.

Investment Firm5
Axil CapitalAxil Capitalward area of Tokyo, Tokyo, JPest. 2017Axil Capitalward area of Tokyo, Tokyo, JP · est. 2017

Axil Capital: A venture capital firm specializing in early-stage biomedical and healthcare investments.

Investment Firm50
Hookipa Pharma
Hookipa Pharma
Public$284.8M1362011New York City, NY, US
Board Member· Board

Leadership at Hookipa Pharma

Joern AldagJoern AldagCEO
Christoph LengauerChristoph LengauerBoard Member
Andreas BergthalerAndreas BergthalerCo-Founder
Katherine CohenKatherine CohenCo-Founder
Rolf M. ZinkernagelRolf M. ZinkernagelCo-Founder
Daniel PinschewerDaniel PinschewerCo-Founder

Similar to Hookipa Pharma

ImmunomeImmunomeExton, PA, USCancer Therapiesest. 2008ImmunomeExton, PA, US · est. 2008

Immunome, a Philadelphia-based biotech company, develops innovative cancer immunotherapies.

Public · $218.9M48
Novita PharmaceuticalsNovita PharmaceuticalsNew York City, NY, USCancer Drugsest. 2010Novita PharmaceuticalsNew York City, NY, US · est. 2010

Novita Pharmaceuticals: Developing and providing cancer-treatment drugs since 2010, based in New York.

Series A · $8.5M7
INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
ImmunophotonicsImmunophotonicsColumbia, MO, USCancer Treatments, Vaccinesest. 2008ImmunophotonicsColumbia, MO, US · est. 2008

ImmunoPhotonics: Pioneering immunotherapy cancer treatments and vaccines since 2008.

Series A · $30.4M15

Jan Van De Winkel's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakLee Sirg-OoLee Sirg-OoCEO · DunamuChi-hyung SongChi-hyung SongBoard Member · Dunamu

People Similar to Jan Van De Winkel

Andrew MasonAndrew MasonFounder · The PointSanju BansalSanju BansalBoard Member · CventJoe TsaiJoe TsaiCo-Founder · Blue Pool CapitalRob HeyvaertRob HeyvaertCo-Founder · Motive VenturesThomas GlanzmannThomas GlanzmannCo-Founder · MedTech Venture PartnersJohn AbeleJohn AbeleCo-Founder · Boston Scientific